FDA approves Moderna’s next-gen Covid vaccine
The FDA has approved Moderna’s next-generation Covid-19 vaccine, but said that people aged 12 to 64 should only get the shot if they have a health condition that puts them at risk from the virus ...
View Article#ASCO25: Takeda, Protagonist unveil data for rare blood disease drug
CHICAGO — Takeda and Protagonist Therapeutics are on the comeback trail with rusfertide, almost four years after the rare blood disease drug was put on a clinical hold because of safety issues in...
View Article#ASCO25: Researchers debate how best to use checkpoint drugs in earlier cancers
CHICAGO — Checkpoint therapies, which made their name as treatments for patients with metastatic cancer, are now being implemented in a wide range of less-advanced cancers alongside surgery. The goal...
View Article#ASCO25: AstraZeneca details Phase 3 data for oral SERD 'switching' regimen
CHICAGO — AstraZeneca is planting its flag in the oral SERD space, touting positive Phase 3 breast cancer data for a program it expects to exceed more than $5 billion in annual peak sales. The trial ...
View Article#ASCO25: In race with Merus, Bicara makes the case for two-year survival data
CHICAGO — Forced to play defense after its stock price fell 40% last month on competing data, Bicara hopes to win back some favor with new results for its head and neck cancer drug. In the ...
View ArticleVera posts positive Phase 3 rare kidney disease data, but crowded market looms
Vera Therapeutics’ rare kidney disease candidate atacicept appears to have pulled off an unusual trick: being more effective in Phase 3 than it was in Phase 2. In the pivotal ORIGIN 3 trial in the ...
View ArticleBristol Myers and BioNTech make $1.5B upfront deal for PD-L1xVEGF cancer drug
BioNTech bought out its China-based biotech partner Biotheus for $800 million upfront in November. Now, the German drugmaker is set to receive $1.5 billion upfront from Bristol Myers Squibb to...
View ArticleKymera reports Phase 1 data for pill to rival Dupixent
The small biotech Kymera Therapeutics believes it could have a potential oral competitor to the megablockbuster Dupixent. There’s a long road ahead for Kymera’s immunology drug candidate, a protein...
View ArticleSanofi to snap up Blueprint Medicines and mastocytosis drug Ayvakit for $9.1B
In the biggest biopharma deal since January, Sanofi is bolstering its rare immunology offering by acquiring Blueprint Medicines for $9.1 billion. The French drugmaker has agreed to pay $129 per share...
View Article#ASCO25: Enhertu combo has the makings of a new standard in HER2-positive...
CHICAGO — AstraZeneca and Daiichi Sankyo’s Enhertu plus Roche’s Perjeta demonstrated the potential to shake up first-line treatment of some advanced breast cancers, according to a new study. In an...
View ArticlePhase 3 or bust: Why Lilly won't run mid-stage cancer trials
CHICAGO — Self-described “blunt pharma executives” Jake Van Naarden and David Hyman of Eli Lilly sat down Sunday with Endpoints News at the annual ASCO conference. The biggest takeaway from a...
View ArticleKorean startup Curogen seeks US expansion, funding to back autoimmune drugs
A South Korean biotech working on multi-specific autoimmune disease treatments is looking to make a leap into the US. Curogen, based in Seoul and backed by local investors, announced Monday that it...
View ArticleSanofi pays out two STAT6 milestones; Theravance sells more Trelegy royalties
Plus, news about Trevi Therapeutics, Zai Lab, Xilio Therapeutics, Novartis, SpyGlass, atai Life Sciences and Beckley Psytech: Sanofi’s STAT6 milestones: The French pharma giant will pay a $15 million...
View ArticleRegeneron makes $80M obesity deal with Hansoh
Regeneron has followed in Merck’s footsteps by licensing an obesity candidate from the China-based biotech Hansoh Pharma. But Regeneron got a much more advanced candidate — and for less. The US company...
View ArticleLaid-off FDA workers wait in limbo, collecting pay and wondering what's next
Monday was supposed to be an FDA lawyer’s last day of work for the federal government. Since being told on April 1 that he would be fired as part of the Trump administration’s cuts, on ...
View ArticleFDA proposes smaller 2026 budget with more user fees than 2025
FDA Commissioner Marty Makary is calling on Congress to fill the agency's coffers next year with 4% less than 2025, including an 11% reduction in taxpayer funds but 4% more industry user fees. The...
View Article#ASCO25: Brain cancer cell therapies make early strides
Early efforts to use cell therapies for aggressive brain cancers are showing promise in a few patients, according to new data released at ASCO this past weekend, with some experiencing long responses...
View ArticleQ&A: Sandoz CEO talks generic GLP-1s, Trump's tariffs, Mark Cuban's company
Richard Saynor’s journey to becoming a self-described patent destroyer was largely by accident. Saynor has been CEO of Sandoz since 2019, but he started his career as a pharmacist before finding the...
View ArticlePyx Health buys FarmboxRx to reach more Medicaid and Medicare members
Pyx Health, built to support people through loneliness, has bought food delivery startup FarmboxRx to reach more members on Medicare and Medicaid plans. The acquisition announced Tuesday includes a...
View Article
